BioSpace News Archive

Drug Development

BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington’s Disease

Asklepios BioPharmaceutical, Inc., a wholly owned and independently operated subsidiary of Bayer AG, has received clearance to conduct a Phase I/II trial for its novel Huntington’s Disease gene therapy, BV-101, in France through its subsidiary BrainVectis.

August 23, 2022
·
6 min read
Business

Isofol Medical AB (publ) publishes interim report, January-June 2022

Isofol Medical AB, announced that the company’s interim report for January-June 2022 is now available on the company’s website.

August 23, 2022
·
4 min read
Pharm Country

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

HUTCHMED Limited announces that initial results of the multi-regional clinical trial of fruquintinib, FRESCO-2, will be presented at the upcoming European Society for Medical Oncology Congress 2022, taking place on September 9-13, 2022.

August 23, 2022
·
9 min read
Business

Mainz Biomed Appoints Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the appointment of Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board.

August 23, 2022
·
8 min read
Zerion Pharma and Hovione extend partnership to cover use of the Dispersome® technology platform in nutraceuticals

AUGUST 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION) and Hovione today announced an extension of their collaboration on ZERION’s Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility.

August 23, 2022
·
5 min read
Genetown

KalVista Pharmaceuticals Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals, Inc. announced the initiation of the KONFIDENT-S open label extension study for its ongoing Phase 3 KONFIDENT study of sebetralstat for the on-demand treatment of hereditary angioedema attacks.

August 23, 2022
·
4 min read
Drug Development

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT199 for Advanced Solid Tumors

Phanes Therapeutics, Inc., an emerging leader in innovative discovery research and clinical development in oncology, announced that the first patient has been dosed in the phase 1 clinical study of PT199, an anti-CD73 monoclonal antibody for the treatment of multiple advanced solid tumors.

August 23, 2022
·
2 min read
Business

BerGenBio reports second quarter and half year 2022 financial results and provides business update

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced financial results for the second quarter and half year ended June 30, 2022 and provided a business update.

August 23, 2022
·
7 min read
Innate Pharma to Participate in Upcoming Investor Conferences - Aug 23, 2022

Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming investor conferences.

August 23, 2022
·
3 min read
Immunovia to present at Gilmartin Group’s Emerging Growth Company Showcase

Immunovia announced it will participate in Gilmartin Group’s Emerging Growth Company Showcase on August 31, 2022.

August 23, 2022
·
1 min read